PT-141: The CNS-Acting Melanocortin Peptide
PT-141 (Bremelanotide) is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that acts primarily through the melanocortin-4 receptor (MC4R) in the central nervous system. Originally developed from research on the tanning peptide Melanotan II, PT-141 was discovered serendipitously when researchers observed its effects on sexual arousal during melanocortin peptide studies (Hadley and Dorr, 2006).
PT-141 received FDA approval in 2019 under the trade name Vyleesi (AMAG Pharmaceuticals) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first FDA-approved medication to act through melanocortin receptor pathways for this indication.
Molecular Profile
- Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
- Amino acids: 7 (cyclic heptapeptide with modifications)
- Molecular weight: ~1,025.2 Da
- CAS number: 189691-06-3
- Parent compound: Derived from Melanotan II, itself an analog of α-MSH
- Key receptor: MC4R (melanocortin-4 receptor)
- FDA approval: 2019, as Vyleesi for HSDD in premenopausal women
- Administration: Subcutaneous injection
Mechanism of Action
PT-141 acts as an agonist at melanocortin receptors, with highest affinity for MC4R and MC3R. Unlike PDE5 inhibitors (e.g., sildenafil) that act on peripheral vascular mechanisms, PT-141 acts centrally in the brain through hypothalamic melanocortin pathways (Molinoff et al., 2003):
- MC4R activation: Binding to MC4R in the hypothalamus and limbic system modulates neural circuits involved in sexual arousal and desire
- Dopaminergic modulation: MC4R activation increases dopamine release in mesolimbic pathways associated with reward and motivation
- Oxytocin pathway: Melanocortin signaling in the paraventricular nucleus stimulates oxytocin release, which contributes to arousal responses
- Central vs. peripheral: The mechanism of action is primarily central nervous system-mediated, distinguishing it from peripherally-acting compounds
Research Area 1: Sexual Function Research
The seminal discovery of PT-141's effects on sexual function came from Melanotan II studies. Diamond et al. (2004) reported that male subjects receiving Melanotan II for tanning research experienced unexpected increases in erectile activity. PT-141 was subsequently developed to isolate the melanocortin-mediated sexual effects without the melanogenic (tanning) activity of Melanotan II.
Rosen et al. (2004) conducted the first controlled trial of PT-141 in males with erectile dysfunction, demonstrating significant improvements in erectile function compared to placebo. The responses occurred in patients who had failed PDE5 inhibitor therapy, suggesting a complementary mechanism of action.
Research Area 2: FDA Approval and Clinical Trials
The RECONNECT Phase 3 clinical trials (Kingsberg et al., 2019) evaluated Bremelanotide (PT-141) in premenopausal women with HSDD. The studies demonstrated statistically significant increases in sexual desire, as measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) and the Female Sexual Function Index (FSFI) desire domain scores.
These results led to FDA approval in June 2019, making PT-141 the first melanocortin-based medication approved for any sexual function indication, and the first centrally-acting medication approved specifically for HSDD in women.
Research Area 3: Melanocortin Receptor Pharmacology
PT-141 has served as a valuable pharmacological tool for understanding the melanocortin receptor system in the central nervous system. Hadley and Dorr (2006) reviewed how PT-141 research expanded understanding of MC4R's roles beyond energy homeostasis and weight regulation to include sexual behavior and autonomic nervous system function.
The compound's selectivity profile — activating MC4R and MC3R while having lower affinity for MC1R (the skin pigmentation receptor) — illustrates the diversity within the melanocortin receptor family and the possibility of developing pathway-specific therapeutics from melanocortin peptide scaffolds.
Research Area 4: Neurological and Behavioral Effects
MC4R activation by compounds like PT-141 influences multiple behavioral domains beyond sexual function. Giuliano et al. (2006) demonstrated that melanocortin receptor activation modulated penile erection through central neural pathways distinct from spinal reflex mechanisms, involving descending projections from the paraventricular nucleus.
Research has also identified that MC4R agonism influences social behavior, motivation, and stress responses, consistent with the receptor's broad expression pattern in limbic and hypothalamic brain regions. These observations have expanded research interest in melanocortin peptides beyond sexual function.
Research Area 5: Side Effect Profile and Tolerability
Clinical trials provided detailed characterization of PT-141's tolerability profile. The most common side effects observed in clinical studies were nausea (approximately 40% of subjects in clinical trials), flushing, and headache (Kingsberg et al., 2019). The nausea was typically mild to moderate and decreased with repeated use.
Notably, PT-141 produced transient increases in blood pressure in clinical studies (mean increase of approximately 2-3 mmHg systolic), leading to a labeled contraindication in patients with uncontrolled hypertension. These cardiovascular effects are consistent with melanocortin receptor-mediated sympathetic nervous system activation.
Current Research Status
PT-141 (Bremelanotide/Vyleesi) is commercially available as an FDA-approved medication. Ongoing research includes investigation of melanocortin receptor pharmacology, potential applications in male sexual dysfunction, and exploration of alternative delivery methods. The compound's unique central mechanism of action through melanocortin pathways continues to drive interest in melanocortin biology research more broadly.
Research Disclaimer
This article is for educational and informational purposes only. BeaCapra supplies research peptides for laboratory and research use. Nothing in this article constitutes medical advice.